Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Clinigen gets rights to Novartis' Cardioxane

Executive Summary

Specialty pharmaco Clinigen Group PLC has acquired Novartis AG’s cancer drug Cardioxane (dexrazoxane) for $33mm in cash, payable in two tranches. Clinigen will now assume responsibility for manufacturing, registration, distribution, and commercialization of the product in territories where marketing authorizations exist, including European, Asian, and Latin American countries.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)
    • Reverse Licensing

Related Companies